Ondansetron/rizatriptan oral transmucosal film

Drug Profile

Ondansetron/rizatriptan oral transmucosal film

Alternative Names: MSRX-202; Rizatriptan/ondansetron

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MonoSol Rx
  • Class Antiemetics; Antimigraines; Carbazoles; Imidazoles; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Migraine; Nausea

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Migraine(In volunteers) in USA (Transmucosal, Film)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Nausea(In volunteers) in USA (Transmucosal, Film)
  • 12 Feb 2015 Clinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top